Company Overview of Nautilus Neurosciences, Inc.
Nautilus Neurosciences, Inc., a neurology-focused specialty pharmaceutical company, engages in identifying and developing drugs for neurological disorders. It offers CAMBIATM, a prescription medicine for migraine attacks in adults. The company was incorporated in 2009 and is based in Bedminster, New Jersey.
135 Route 202/206
Bedminster, NJ 07921
Founded in 2009
Key Executives for Nautilus Neurosciences, Inc.
Founder, President and Director
Compensation as of Fiscal Year 2015.
Nautilus Neurosciences, Inc. Key Developments
DepoMed Inc. Acquires United States Rights to CAMBIA (Diclofenac Potassium for Oral Solution) Migraine Medicine from Nautilus Neurosciences for $48.7 Million
Dec 17 13
Depomed, Inc. announced that it has acquired the United States rights to CAMBIA(R) (diclofenac potassium for oral solution) from Nautilus Neurosciences for $48.7 million. In addition, Depomed may pay to the company up to an additional $5 million based on the achievement of certain annual net sales. CAMBIA is a non-steroidal anti-inflammatory drug (NSAID) indicated for acute treatment of migraine attacks with or without aura in adults 18 years of age or older. Benefits of CAMBIA acquisition: Bolsters Depomed's portfolio in pain and neurology, specifically strengthening the company's position with neurologists. Secures CAMBIA, the only single agent NSAID in the U.S. specifically indicated for migraine, and immediately increases Depomed's topline with annualized net sales run rate of approximately $18 million over the past 3 months. Adds another growth product to Depomed, as CAMBIA total prescriptions in third quarter 2013 were up more than 30% over the same quarter last year. Creates synergies with Gralise commercial efforts as nearly 70% of CAMBIA prescriptions are written by neurologists and half of these prescribing neurologists are currently Gralise prescribers. Increases the sales support for CAMBIA, moving from the current 35 sales reps with the company to Depomed's existing 155 sales territories, reaching more of the target audience for the drug. Secures a long term revenue stream with settled ANDA litigation and generic entry expected in January 2023. Transaction details: Depomed acquired all US rights to CAMBIA in return for $48.7 million cash, $7.5 million of which will be deposited into an escrow account. Depomed will pay the company up to $5 million in net sales payments and will assume certain liabilities, including third party royalties and up to $10 million in third party sales milestone payments.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries